Medline, Inc. Free cash flow decreased by 45.9% to $316.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.9%, from $584.00M to $316.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
free_cash_flow| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $352.50M | $352.50M | $352.50M | $352.50M | $353.75M | $353.75M | $353.75M | $353.75M | $584.00M | $316.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.4% | +0.0% | +0.0% | +0.0% | +65.1% | -45.9% |
| YoY Change | — | — | — | — | +0.4% | +0.4% | +0.4% | +0.4% | +65.1% | -45.9% |